InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.013 -0.005 (-27.78%)+
Announcement
Release
21 Oct 2026 3:40PM
Price at Release
$0.018
Full Release
download
Summary
Avecho Biotechnology Limited (ASX: AVE) responded to an ASX price query dated 21 October 2026 regarding a rise in its share price from $0.014 on 20 October 2026 to $0.019 on 21 October 2026 and increased trading volume, stating that it was not aware of any undisclosed information that could explain the recent trading, that question 2 was not applicable, and that it had no other explanation for the movement in its securities; the company also confirmed it was complying with the ASX Listing Rules, particularly Listing Rule 3.1 on continuous disclosure, and that its responses had been authorised and approved by the Board, while the attached ASX letter set out the query, response deadline, and the potential need for a trading halt or suspension if a sufficient response was not provided.
Key Points
  • ASX queried Avecho Biotechnology Limited about a price rise and increased trading volume in its securities on 21 October 2026.
  • Avecho said it was not aware of any information that had not been announced to the market which could explain the recent trading.
  • Avecho marked question 2 as not applicable because it said there was no undisclosed information.
  • Avecho said it had no explanation for the recent trading in its securities.
  • Avecho confirmed compliance with the ASX Listing Rules, especially Listing Rule 3.1.
  • Avecho confirmed the response was authorised and approved by the Board.
  • The ASX letter noted the share price had moved from $0.014 on 20 October 2026 to $0.019 on 21 October 2026.
  • ASX requested a response by 3:30 PM AEDT on 21 October 2026 and noted a trading halt or suspension could apply if needed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.